Barclays Raises Price Target for Addus HomeCare (ADUS)

Barclays raised the price target for Addus HomeCare (ADUS) from $83 to $109, a 31.33% increase. The analyst maintained the "Underweight" rating. Other analysts have raised price targets and maintained "Buy" ratings. The average target price is $140.55, with a high estimate of $160 and a low of $109. The average brokerage recommendation is 1.8, indicating "Outperform" status. GF Value estimates a one-year fair value of $132.84, suggesting a 16.33% upside from the current price.

Barclays has raised the price target for Addus HomeCare (ADUS) from $83 to $109, a 31.33% increase, while maintaining an "Underweight" rating [1]. This move comes as other analysts have also raised their price targets and maintained "Buy" ratings for the company. The average target price is now $140.55, with a high estimate of $160 and a low of $109. The average brokerage recommendation is 1.8, indicating an "Outperform" status. GF Value estimates a one-year fair value of $132.84, suggesting a 16.33% upside from the current price.

Analysts' ratings and price targets provide valuable insights into the market's perception of Addus HomeCare. For instance, TD Cowen analyst Ryan Langston raised the price target to $139 from $135, citing positive fundamentals and additional revenues/EBITDA from the Helping Hands segment [1]. JMP Securities analysts have maintained their "Buy" rating with a price target of $150, highlighting the company's strong growth prospects [1].

Addus HomeCare operates in the home care services sector, providing personal care, hospice, and home health services. The company's revenue growth over the past three months has been significant, with a 21.79% increase, outperforming industry averages [2]. Additionally, the company's net margin and return on equity (ROE) are above industry benchmarks, indicating strong financial health [2].

While analyst ratings can influence investment decisions, it is crucial for investors to consider the company's fundamentals and their own risk tolerance. The recent analyst actions reflect a positive outlook on Addus HomeCare, but investors should conduct their own research and make informed decisions.

References:
[1] https://intellectia.ai/news/stock/barclays-maintains-underweight-on-addus-homecare-raises-price-target-to-109
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/47207246/forecasting-the-future-5-analyst-projections-for-addus-homecare